RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
An antidepressant-related pharmacological signature for positive allosteric modulators of α2/3-containing GABA
A receptors.
Methuku, K. R., Li, X., Cerne, R., Gleason, S. D., Schkeryantz, J. M., Tiruveedhula, V. V. N. P. B., Golani, L. K., Li, G., Poe, M. M., Rahman, M. T., Cook, J. M., Fisher, J. L., & Witkin, J. M. (2018). An antidepressant-related pharmacological signature for positive allosteric modulators of α2/3-containing GABA
A receptors.Pharmacology Biochemistry and Behavior, 170, 9-13. https://doi.org/10.1016/j.pbb.2018.04.009
Data from transgenic animals and novel pharmacological agents has realigned scientific scrutiny on the therapeutic potential of positive allosteric modulators (PAMs) of alpha 2/3-containing GABA(A) receptors. Evidence for analgesic, anticonvulsant, and anxiolytic activity of alpha 2/3-selective PAMs has been presented along with the clinical potential for a milder motor-impacting profile compared to non-selective GABA(A) receptor PAMs. A new series of alpha 2/3-selective PAMs was recently introduced which has anxiolytic and anticonvulsant activity in rodent models. These molecules also produce efficacy against pain in multiple animal models. Additionally, co-morbid states of depression are prevalent among patients with pain and patients with anxiety. Compounds were shown to be selective for alpha 2 and alpha 3 constructs over alpha 1(except KRM-II-82), alpha 4, alpha 5, and alpha 6 proteins in electro-physiological assays in transfected HEK-293T cells. Utilizing the forced-swim assay in mice that detects conventional and novel antidepressant drugs, we demonstrate for the first time that alpha 2/3-selective PAMs are active in the forced-swim assay at anxiolytic-producing doses. In contrast, activity in a related model, the tail-suspension test, was not observed. Diazepam was not active in the forced-swim assay when given alone but produced an antidepressant-like effect in mice when given in conjunction with the alpha 1preferring antagonist, beta-CCT, that attenuated the motor-impairing effects of diazepam. We conclude that these alpha 2/3-selective PAMs deserve further scrutiny for their potential treatment of major depressive disorder. If effective, such a mechanism could add a beneficial antidepressant component to the anxiolytic, analgesic, and anticonvulsant spectrum of effects of these compounds.